February 6, 2024 - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.
The abstract, titled ACD856 is a biased positive allosteric modulator of Trk-receptors – Enhances neurite outgrowth but do not affect pain signaling, will be presented at the international conference AD/PD 2024 on Alzheimer's, Parkinson's and Related Neurological Disorders by Pontus Forsell, Head of Discovery and Research at AlzeCure. Co-authors are Veronica Lidell, Azita Rasti, Gunnar Nordvall and Johan Sandin.
The presentation includes study results showing that ACD856, the lead drug candidate in the NeuroRestore platform being developed with a focus on Alzheimer's disease, selectively appears to potentiate some signaling pathways, but not others. New preclinical data show that the substance stimulates the growth of nerve cell projections, which can promote nerve cell communication, but does not affect other functions, such as pain signaling. Previous studies have also been able to show that ACD856 improves memory, synaptic plasticity and has neuroprotective properties... AlzeCure Pharma's Press Release -
